BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24921639)

  • 1. BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity.
    Bledsoe JR; Kamionek M; Mino-Kenudson M
    Am J Surg Pathol; 2014 Oct; 38(10):1418-28. PubMed ID: 24921639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer.
    Schafroth C; Galván JA; Centeno I; Koelzer VH; Dawson HE; Sokol L; Rieger G; Berger MD; Hädrich M; Rosenberg R; Nitsche U; Schnüriger B; Langer R; Inderbitzin D; Lugli A; Zlobec I
    Oncotarget; 2015 Dec; 6(39):41453-63. PubMed ID: 26496026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
    Lasota J; Kowalik A; Wasag B; Wang ZF; Felisiak-Golabek A; Coates T; Kopczynski J; Gozdz S; Miettinen M
    Am J Surg Pathol; 2014 Sep; 38(9):1235-41. PubMed ID: 24832158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
    Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J
    Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
    Estrella JS; Tetzlaff MT; Bassett RL; Patel KP; Williams MD; Curry JL; Rashid A; Hamilton SR; Broaddus RR
    Mol Cancer Ther; 2015 Dec; 14(12):2887-95. PubMed ID: 26438153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
    Adackapara CA; Sholl LM; Barletta JA; Hornick JL
    Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.
    Rössle M; Sigg M; Rüschoff JH; Wild PJ; Moch H; Weber A; Rechsteiner MP
    Virchows Arch; 2013 Nov; 463(5):623-31. PubMed ID: 24085553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
    Ilie MI; Long-Mira E; Hofman V; Mouroux J; Vignaud JM; Gauchotte G; Begueret H; Merlio JP; Emile JF; Hébuterne X; Hofman P
    Pathology; 2014 Jun; 46(4):311-5. PubMed ID: 24798160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.
    Tetzlaff MT; Pattanaprichakul P; Wargo J; Fox PS; Patel KP; Estrella JS; Broaddus RR; Williams MD; Davies MA; Routbort MJ; Lazar AJ; Woodman SE; Hwu WJ; Gershenwald JE; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2015 Aug; 46(8):1101-10. PubMed ID: 26058727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
    Dvorak K; Higgins A; Palting J; Cohen M; Brunhoeber P
    Pathol Oncol Res; 2019 Jan; 25(1):349-359. PubMed ID: 29127628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.
    Dvorak K; Aggeler B; Palting J; McKelvie P; Ruszkiewicz A; Waring P
    Pathology; 2014 Oct; 46(6):509-17. PubMed ID: 25014730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF V600E mutation-specific antibody: A review.
    Ritterhouse LL; Barletta JA
    Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma.
    Sajanti S; Sirniö P; Väyrynen JP; Tuomisto A; Klintrup K; Mäkelä J; Ristimäki A; Mäkinen MJ
    Virchows Arch; 2014 Jun; 464(6):637-43. PubMed ID: 24722974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of immunohistochemistry for the detection of the BRAF V600E mutation in colorectal carcinoma.
    Ioannou M; Papamichali R; Samara M; Paraskeva E; Papacharalambous C; Baxevanidou K; Koukoulis G
    J BUON; 2016; 21(3):618-25. PubMed ID: 27569082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
    Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms.
    Vakiani E; Yaeger R; Brooke S; Zhou Y; Klimstra DS; Shia J
    Appl Immunohistochem Mol Morphol; 2015 Jul; 23(6):438-43. PubMed ID: 25517872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrapatient homogeneity of BRAFV600E expression in melanoma.
    Menzies AM; Lum T; Wilmott JS; Hyman J; Kefford RF; Thompson JF; O'Toole S; Long GV; Scolyer RA
    Am J Surg Pathol; 2014 Mar; 38(3):377-82. PubMed ID: 24335665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma.
    Ida CM; Vrana JA; Rodriguez FJ; Jentoft ME; Caron AA; Jenkins SM; Giannini C
    Acta Neuropathol Commun; 2013 May; 1():20. PubMed ID: 24252190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.
    Affolter K; Samowitz W; Tripp S; Bronner MP
    Genes Chromosomes Cancer; 2013 Aug; 52(8):748-52. PubMed ID: 23650027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.